Gateway Wealth Partners LLC purchased a new stake in SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 11,938 shares of the exchange traded fund’s stock, valued at approximately $1,525,000.
A number of other hedge funds have also recently made changes to their positions in XBI. Financial Life Planners purchased a new stake in shares of SPDR S&P Biotech ETF in the first quarter worth $27,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in SPDR S&P Biotech ETF during the fourth quarter valued at $27,000. Intesa Sanpaolo Wealth Management purchased a new position in SPDR S&P Biotech ETF during the fourth quarter worth about $30,000. SHP Wealth Management purchased a new position in SPDR S&P Biotech ETF during the fourth quarter worth about $31,000. Finally, Legacy Wealth Managment LLC ID bought a new position in SPDR S&P Biotech ETF in the 4th quarter worth about $32,000.
SPDR S&P Biotech ETF Stock Down 0.5%
Shares of NYSEARCA XBI opened at $149.78 on Wednesday. The stock’s 50-day simple moving average is $145.16 and its two-hundred day simple moving average is $133.90. SPDR S&P Biotech ETF has a twelve month low of $84.39 and a twelve month high of $165.71. The firm has a market capitalization of $10.09 billion, a P/E ratio of 11.47 and a beta of 0.82.
SPDR S&P Biotech ETF Profile
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.
Featured Articles
- Five stocks we like better than SPDR S&P Biotech ETF
- These 3 Stocks Have Soared in 2026—Can They Keep Climbing?
- Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy Story
- Rambus: Another AI Phoenix Ready to Rise From the Ashes of Correction
- Chips & Clips: Memory Tariffs Rewire Tech Supply Chains
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.
